Objective To investigate the effects of candesartan and benazepril on cardiac function,laboratory indicators,and cardiovascular adverse events in patients with chronic myocardial infarction and chronic heart failure.Methods 102 patients with chronic myocardial infarction and chronic heart failure diagnosed and treated at our hospital from December,2016 to June,2017 were included into this study,All the patients were divided into an observation group (n=51) and a control group (n=51) using digital random table method.The control group were conventionally treated;in addition,the observation group were treated with candesartan and benazepril.Both groups were continuously treated for 8 weeks.The cardiac function and vascular endothelial function of the 2 groups were measured and compared.The cardiovascular adverse events of 2 groups were compared.Results The SV,LVEF,FS,and CO of 2 groups were significantly higher after than before the treatment in both groups(P ＜ 0.05 or P ＜ 0.01),and were significantly higher in the observation group than in the control group after the treatment (P ＜ 0.05 or P ＜ 0.01).The FMD was significantly higher and the hs-CRP was significantly lower after than before the treatment in both groups,and there were statistical differences between the 2 groups after the treatment (P ＜ 0.01).There were no statistical differences in GMD of the 2 groups bettween before and after treatment and between these two groups (P ＞ 0.05).During the follow-up period,there was no statistical difference in mortality between these 2 groups (P ＞ 0.05).The incidences of stroke and malignant arrhythmia were significantly higher in the control group than in the observation group,with statistical differences (P ＜ 0.05).Conclusions Candesartan combined with benazepril for patients with chronic myocardial infarction and chronic heart failure can improve their cardiac function and vascular endothelial function,and has a low incidence of adverse cardiovascular events and exact effect,so it is worth being clinically generalized.%目的 探讨坎地沙坦、贝那普利两种药物联合使用在陈旧性心肌梗死合并慢性心力衰竭中的治疗价值及对患者心脏功能、实验室指标及心血管不良事件的影响.方法 择取2016年12月至2017年6月经本院诊治为陈旧性心肌梗死合并慢性心力衰竭患者102例为研究对象,并采用数字随机表法分为观察组和对照组,各51例.对照组常规治疗,观察组在此基础上采用坎地沙坦、贝那普利两种药物联合治疗.两组均连续治疗8周.测定并比较两组心功能、血管内皮功能;统计并比较两组心血管不良事件.结果 治疗后,两组SV、LVEF、FS、CO均较治疗前明显升高(P＜0.05或P＜0.01),且观察组显著高于对照组(P＜ 0.05或P＜0.01).治疗后,两组FMD相比于治疗前明显升高,hs-CRP水平相比于治疗前明显降低(P＜ 0.01),且两组间差异有统计学意义(均P＜0.01).GMD治疗前后及组间相比,差异均无统计学意义(均P＞ 0.05).随访期间,两组病死率经统计学比较,差异无统计学意义(P＞0.05);对照组脑卒中、恶性心律失常发生率显著高于观察组,差异有统计学意义(P＜0.05).结论 对陈旧性心肌梗死合并慢性心力衰竭患者给予坎地沙坦联合贝那普利治疗可明显改善其心功能和血管内皮功能,且心血管不良事件发生率低,效果确切,值得临床推广.
展开▼
